AL Amyloidosis is a rare hematologic disease caused by the
buildup of an abnormal protein called amyloid in organs and tissues. Amyloid
proteins accumulate in organs including the heart, liver, kidneys, nervous
system, and digestive tract. This prevents the organs from working properly.
Amyloidosis diagnosis involves blood tests, imaging tests, heart tests, kidney
function tests and tissue biopsy to confirm amyloid deposits. Special
laboratory tests help differentiate types of amyloid proteins. AL
Amyloidosis Diagnostics Market include biomarkers testing, imaging,
genotyping and histology.
buildup of an abnormal protein called amyloid in organs and tissues. Amyloid
proteins accumulate in organs including the heart, liver, kidneys, nervous
system, and digestive tract. This prevents the organs from working properly.
Amyloidosis diagnosis involves blood tests, imaging tests, heart tests, kidney
function tests and tissue biopsy to confirm amyloid deposits. Special
laboratory tests help differentiate types of amyloid proteins. AL
Amyloidosis Diagnostics Market include biomarkers testing, imaging,
genotyping and histology.
The AL amyloidosis diagnostic market is estimated
to be valued at USD 1.068 billion in 2024 and is expected
to reach USD 1.693 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to
2031.
to be valued at USD 1.068 billion in 2024 and is expected
to reach USD 1.693 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to
2031.
Key Takeaways
Key players: Key players operating
in the amyloidosis diagnostics market are Pfizer Inc., Prothena Corporation
plc, Alnylam Pharmaceuticals, Inc., GlaxoSmithKline plc., Celgene Corporation,
BASF SE, AKCEA Therapeutics, and Ionis Pharmaceuticals.
in the amyloidosis diagnostics market are Pfizer Inc., Prothena Corporation
plc, Alnylam Pharmaceuticals, Inc., GlaxoSmithKline plc., Celgene Corporation,
BASF SE, AKCEA Therapeutics, and Ionis Pharmaceuticals.
Growing demand: There is growing
demand for amyloidosis diagnostics due to rising awareness about the disease
and its symptoms. The diagnosis rates have improved in recent years due to
availability of advanced diagnostic tools and tests.
demand for amyloidosis diagnostics due to rising awareness about the disease
and its symptoms. The diagnosis rates have improved in recent years due to
availability of advanced diagnostic tools and tests.
Global expansion: Key market players
are expanding their geographical footprint by strengthening their distribution
networks worldwide especially in developing nations. Companies are also
collaborating with local players to enhance testing capabilities in new
potential markets.
are expanding their geographical footprint by strengthening their distribution
networks worldwide especially in developing nations. Companies are also
collaborating with local players to enhance testing capabilities in new
potential markets.
Market drivers
One of the key drivers for amyloidosis diagnostics market is growing. The
policy of regular physical examinations for the elderly has increased awareness
of the disease. With rising health awareness, governments across major
countries have rolled out screening programs for early detection of rare
diseases like amyloidosis. Regular health checkups help identify initial
symptoms and pursue timely treatment. This is significantly boosting the demand
for diagnostic testing and driving the amyloidosis diagnostics market growth.
policy of regular physical examinations for the elderly has increased awareness
of the disease. With rising health awareness, governments across major
countries have rolled out screening programs for early detection of rare
diseases like amyloidosis. Regular health checkups help identify initial
symptoms and pursue timely treatment. This is significantly boosting the demand
for diagnostic testing and driving the amyloidosis diagnostics market growth.
Impact of geopolitical situation on AL
Amyloidosis Diagnostics market growth
Amyloidosis Diagnostics market growth
The ongoing geopolitical conflicts and tensions across various regions have
created uncertainties which have negatively impacted the global AL Amyloidosis
Diagnostics market. The Russia-Ukraine war has disrupted the supply chains and
export-import activities. This has affected the availability of key diagnostic
reagents and instruments in the European countries. Many leading diagnostic
device manufacturers have facilities located in these regions and the ongoing
war has hampered their production capabilities. The rising inflation rates and
economic downturn in major markets like US and Europe have tightened the
healthcare budgets of many countries which may decrease the funding for new
diagnostic tests and research activities. The political instability and
conflicts in Middle Eastern countries also add to the challenges. It has become
difficult to conduct clinical trials and research collaborations across
conflict zones. The market players need to closely monitor the geopolitical
developments and diversify their manufacturing/supply chain networks to
multiple regions to ensure steady product supply. The companies may also focus
on cost optimization and development of low-cost point-of-care solutions to
increase accessibility in low resource regions impacted due to funding
constraints.
created uncertainties which have negatively impacted the global AL Amyloidosis
Diagnostics market. The Russia-Ukraine war has disrupted the supply chains and
export-import activities. This has affected the availability of key diagnostic
reagents and instruments in the European countries. Many leading diagnostic
device manufacturers have facilities located in these regions and the ongoing
war has hampered their production capabilities. The rising inflation rates and
economic downturn in major markets like US and Europe have tightened the
healthcare budgets of many countries which may decrease the funding for new
diagnostic tests and research activities. The political instability and
conflicts in Middle Eastern countries also add to the challenges. It has become
difficult to conduct clinical trials and research collaborations across
conflict zones. The market players need to closely monitor the geopolitical
developments and diversify their manufacturing/supply chain networks to
multiple regions to ensure steady product supply. The companies may also focus
on cost optimization and development of low-cost point-of-care solutions to
increase accessibility in low resource regions impacted due to funding
constraints.
Geographical regions with high market
concentration of AL Amyloidosis Diagnostics
concentration of AL Amyloidosis Diagnostics
The North America region currently dominates the global AL Amyloidosis
Diagnostics market in terms of revenue contribution. The US accounts for the
major share due to presence of advanced healthcare infrastructure, rising AL
amyloidosis prevalence rates fueled by aging population, and high adoption of
novel diagnostic technologies among medical professionals. Growing awareness
levels, availability of specialized amyloidosis treatment centers and favorable
reimbursement policies also support the market growth in the region. Europe is
the second largest regional market driven by presence of leading diagnostic
players and increasing funding for rare disease research. Germany, France and
the UK contribute significantly to the European market valued. The rising
healthcare expenditures and expansion of private insurance coverage in
countries like China, Japan and India are creating high growth potential for
the AL Amyloidosis Diagnostics market in the Asia Pacific region.
Diagnostics market in terms of revenue contribution. The US accounts for the
major share due to presence of advanced healthcare infrastructure, rising AL
amyloidosis prevalence rates fueled by aging population, and high adoption of
novel diagnostic technologies among medical professionals. Growing awareness
levels, availability of specialized amyloidosis treatment centers and favorable
reimbursement policies also support the market growth in the region. Europe is
the second largest regional market driven by presence of leading diagnostic
players and increasing funding for rare disease research. Germany, France and
the UK contribute significantly to the European market valued. The rising
healthcare expenditures and expansion of private insurance coverage in
countries like China, Japan and India are creating high growth potential for
the AL Amyloidosis Diagnostics market in the Asia Pacific region.
Fastest growing region in the AL
Amyloidosis Diagnostics market
Amyloidosis Diagnostics market
The Asia Pacific region, excluding Japan, is emerging as the fastest growing
regional market for AL Amyloidosis Diagnostics. There is a continuous increase
in geriatric population susceptible to AL amyloidosis and related conditions in
developing Asian countries. This is elevating the demand for advanced
diagnostic technologies. Additionally, governments are investing heavily to
strengthen the healthcare infrastructure across nations like India, China and
South Korea. The diagnostic device manufacturers are also shifting their focus
towards the emerging Asian markets seeing the future growth prospects.
Increasing awareness initiatives by NGOs and patient advocacy groups are
boosting the early diagnosis rates. Rising medical tourism and expansion of
private hospitals/clinics will further support the market growth in the Asia
Pacific region. The market is expected to grow at a CAGR of over 8% during the
forecast period.
regional market for AL Amyloidosis Diagnostics. There is a continuous increase
in geriatric population susceptible to AL amyloidosis and related conditions in
developing Asian countries. This is elevating the demand for advanced
diagnostic technologies. Additionally, governments are investing heavily to
strengthen the healthcare infrastructure across nations like India, China and
South Korea. The diagnostic device manufacturers are also shifting their focus
towards the emerging Asian markets seeing the future growth prospects.
Increasing awareness initiatives by NGOs and patient advocacy groups are
boosting the early diagnosis rates. Rising medical tourism and expansion of
private hospitals/clinics will further support the market growth in the Asia
Pacific region. The market is expected to grow at a CAGR of over 8% during the
forecast period.
Get more insights on : AL
Amyloidosis Diagnostics Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold
in the market research industry. She specializes in writing well-researched
articles from different industries, including food and beverages, information
and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Please follow and like us:
